IP-10, formally known as CXCL10, is a small signaling protein (a chemokine) that your immune system produces to recruit certain white blood cells to sites of infection, injury, or inflammation. It earned its original name, interferon gamma-induced protein 10, because cells release it in response to interferons, the alarm signals your body sends out when it detects a virus or other threat. Over the past two decades, CXCL10 has attracted growing interest as a blood and urine biomarker because its levels rise sharply in a wide range of diseases, from tuberculosis and COVID-19 to lupus, rheumatoid arthritis, and certain cancers. Understanding what drives those levels up or down, and what a test result actually means, requires a closer look at the protein’s biology and the conditions it tracks.
How CXCL10 Works
CXCL10 is produced mainly by monocytes, endothelial cells, fibroblasts, and certain tissue cells when they are exposed to interferons, particularly interferon-gamma and type I interferons like interferon-beta. The production pathway involves a signaling cascade in which interferon triggers a protein complex to enter the cell nucleus and switch on the CXCL10 gene, ramping up production of the chemokine for release into surrounding tissue and the bloodstream.1PubMed Central. IFNβ-Induced CXCL10 Chemokine Expression Is Regulated by Pellino3 Ligase in Monocytes and Macrophages
Once released, CXCL10 acts as a homing beacon. It binds to a receptor called CXCR3, which sits on the surface of activated T cells, natural killer cells, and some other immune cells. When these CXCR3-bearing cells detect a gradient of CXCL10, they migrate toward the source. This is how the body concentrates its firepower at the right location: an infected lung, an inflamed joint, or a transplanted organ under immune attack. CXCR3 is shared by two other interferon-driven chemokines, CXCL9 and CXCL11, but CXCL10 is often the most abundant of the three and is frequently the one measured in clinical tests.2PubMed Central. CXCR3 in T cell function
Beyond immune cell recruitment, CXCL10 has an anti-angiogenic side. A variant of its receptor, called CXCR3-B, is found on the surface of blood vessel cells. When CXCL10 binds this variant, it inhibits the growth of new blood vessels. Researchers have shown that this effect is mediated by a specific stress-response pathway inside endothelial cells, and that blocking that pathway reverses the growth inhibition.3PubMed. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B This dual role, attracting immune cells while simultaneously restricting blood vessel growth, makes CXCL10 relevant to both infectious disease and cancer biology.
CXCL10 in Viral Infections
Because CXCL10 production is tightly linked to interferon signaling, it spikes early during viral infections. In COVID-19, studies found that CXCL10 concentrations were roughly seven times higher in patients with severe disease compared to healthy controls and about double in severe cases relative to milder ones. Markedly high levels were linked to acute respiratory distress syndrome and neurological complications, making CXCL10 one of the more promising early predictors of a bad outcome.4PubMed Central. What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection? – Section: Severity and Potential Risk Factors of the Disease Separate work confirmed that CXCL10 stood out even among other inflammatory markers, being significantly elevated in mildly symptomatic COVID-19 patients when several other cytokines showed no difference between patient categories.5PubMed Central. Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection
The pattern is not unique to SARS-CoV-2. In influenza, CXCL10 is associated with the severity of both avian strains like H5N1 and H7N9 and human strains like pandemic H1N1, and it has been linked to mortality in these infections.6PubMed. Cytokines Induced During Influenza Virus Infection In hepatitis C, the picture is slightly different: pretreatment CXCL10 levels helped predict who would respond to antiviral therapy. Patients with lower baseline CXCL10 were significantly more likely to clear the virus after treatment, even when they had other factors like high body weight or high viral load working against them.7PubMed. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection In this context, CXCL10 served not as a severity marker but as a gauge of chronic immune activation that made treatment less effective.
Tuberculosis Diagnostics
One of the more developed clinical applications of CXCL10 measurement is in distinguishing active tuberculosis from latent infection, a notoriously difficult diagnostic challenge. In a study comparing plasma chemokines, CXCL10 discriminated active drug-sensitive TB from latent TB with strong accuracy.8Scientific Reports. Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis – Section: Results Research in children found that baseline CXCL10 was elevated in both active TB and latent TB infection, though stimulated levels of IP-10 did not reliably separate the two groups, suggesting that its diagnostic power may depend on how the test is designed.9PLoS ONE. Is IP-10 a Better Biomarker for Active and Latent Tuberculosis in Children than IFNγ? – Section: Results
A large multicentre evaluation found that IP-10 had a higher rate of positive responders than the standard interferon-gamma-based test among non-TB patients, and that a positive IP-10 response was associated with known risk factors for TB exposure. Interestingly, IP-10 appeared less influenced by infections other than TB, which could be an advantage in settings where co-infections are common.10PubMed. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis These features have led to IP-10-based tests being explored as supplements or alternatives to existing interferon-gamma release assays, particularly for populations where those assays perform poorly, like young children and immunocompromised individuals.
Autoimmune Disease and Chronic Inflammation
Elevated CXCL10 is a common thread across a wide range of autoimmune conditions. Blood and tissue levels are increased in rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, and inflammatory myopathies.11PubMed. CXCL10 and autoimmune diseases The reason is straightforward: these diseases involve overactive interferon signaling and chronic immune cell recruitment, exactly the conditions that drive CXCL10 production.
In early rheumatoid arthritis, CXCL10 was the only chemokine out of a panel tested that correlated with multiple standard measures of disease activity, including swollen joint counts and inflammatory blood markers.12PubMed Central. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker – Section: RESULTS In lupus, and specifically in lupus nephritis, serum CXCL10 performed even more impressively, predicting kidney involvement with roughly 96% sensitivity and 94% specificity in one cohort study. Levels tracked closely with urinary protein, kidney function, and disease activity scores.13PubMed Central. Serum CXCL10 as a potential biomarker for lupus nephritis and disease activity: evidence from an Egyptian cohort – Section: RESULTS
In inflammatory bowel disease, CXCL10 and its receptor are more abundant in inflamed gut tissue from patients with active Crohn’s disease and ulcerative colitis compared to those in remission or healthy controls. The chemokine localizes mainly to the cells lining the intestinal surface.14PubMed. Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation – Section: RESULTS Laboratory work in gut tissue models has shown that the intestinal lining itself can actively secrete CXCL10 during colitis, and that another immune signal, IL-17A, normally acts as a brake on CXCL10 production in the gut. When IL-17A is absent, CXCL10 rises further.15PubMed Central. IFN-γ and IL-17A regulate intestinal crypt production of CXCL10 in the healthy and inflamed colon
The Role in Multiple Sclerosis and Neuroinflammation
CXCL10 is also elevated in the cerebrospinal fluid of people with multiple sclerosis, where it correlates with the number of T cells that have crossed into the central nervous system.16PubMed Central. CXCL10 Is Associated with Increased Cerebrospinal Fluid Immune Cell Infiltration and Disease Duration in Multiple Sclerosis – Section: Discussion Research in animal models of MS has added nuance: deleting CXCL10 produced by brain support cells delayed the onset of clinical symptoms and substantially reduced the acute stripping of nerve insulation (demyelination), but did not prevent long-term nerve fiber loss. This suggests CXCL10 drives the early inflammatory attack on myelin but that progressive nerve damage is sustained by other mechanisms.17PubMed Central. Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model
CXCL10 and Type 1 Diabetes
The islets of the pancreas that produce insulin are a well-studied target of CXCL10-driven immune attack. When exposed to CXCL10 directly, human islets show reduced cell survival, impaired insulin secretion, and lower insulin gene activity.18Cell Metabolism. CXCL10 Mediates Beta Cell Failure and Islet Inflammation in Diabetes In pancreatic tissue from people with recent-onset type 1 diabetes, inflamed islets consistently contained elevated CXCL10 alongside immune cells bearing the CXCR3 receptor, pointing to CXCL10 as a central player in the immune cell invasion that destroys insulin-producing cells.19PubMed Central. Islet inflammation and CXCL10 in recent-onset type 1 diabetes
Mice engineered to produce CXCL10 specifically in their islets developed immune cell infiltration in the pancreas and showed early signs of impaired beta cell function, though they did not progress to overt diabetes on their own. However, when these mice were also infected with a virus known to trigger autoimmune diabetes, disease developed faster. This tells us that CXCL10 can set the stage for islet destruction by attracting immune cells, even if an additional trigger is usually needed to push the process over the edge.20The Journal of Immunology. Islet-Specific Expression of CXCL10 Causes Spontaneous Islet Infiltration and Accelerates Diabetes Development
Cancer: Friend and Foe
CXCL10’s relationship with cancer is genuinely two-faced. On one hand, its ability to recruit T cells and natural killer cells into tumors is exactly what the immune system needs to fight cancer. Research has shown that boosting CXCL10 inside tumors, for example by injecting engineered viruses that produce it, can draw more immune cells into the tumor and enhance the effectiveness of checkpoint immunotherapy drugs like anti-PD-1 antibodies.21PubMed Central. CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy CXCL10 has also been proposed as a biomarker for predicting which patients will respond well to immune checkpoint blockade, particularly in tumors with high levels of DNA repair defects, where CXCL10 production tends to be elevated.22PubMed Central. CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors – Section: Discussion
On the other hand, tumor cells can hijack the CXCL10 system for their own benefit. In liver cancer, overexpression of CXCL10 by tumor cells promoted migration, invasion, and metastasis by triggering a process that makes cells more mobile and by activating enzymes that break down surrounding tissue.23PubMed Central. CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma Similarly, in melanoma models, suppressing CXCL10 or its receptor CXCR3 on tumor cells significantly reduced the number of metastatic colonies in the lungs, an effect that held even in mice lacking a functional immune system, which means the metastasis-promoting effect was driven by the tumor cells themselves, not by immune activity.24British Journal of Cancer. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome – Section: Results Pancreatic cancer research has identified the same pro-tumor axis, with CXCL10 driving cell proliferation and invasion through a growth signaling pathway, and pharmacological blockade of the receptor suppressing those effects.25PubMed. CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK/MAPK signaling
Whether CXCL10 helps or hurts in a given cancer likely depends on which cells are doing the producing and which cells are responding. When the immune system generates CXCL10 to recruit cancer-killing T cells, the effect is protective. When the tumor cells themselves produce it and respond to it through autocrine signaling, or when it promotes migration and blood vessel remodeling in their favor, it fuels progression.
Transplant Monitoring
One of the most clinically advanced uses of CXCL10 testing is in kidney transplant medicine. After a transplant, the recipient’s immune system may attack the new organ, and catching rejection early is critical. Traditionally, this requires an invasive biopsy. Urine CXCL10 has emerged as a promising noninvasive alternative because the transplanted kidney itself sheds the chemokine into urine when it is under immune attack. A large body of observational evidence shows that urine CXCL10 can detect both clinically apparent and subclinical rejection in adults and children. When combined with other clinical parameters, it achieves strong diagnostic accuracy, with one multiparameter model reaching diagnostic performance in the range of 81 to 85% accuracy for acute rejection detection.26PubMed Central. Urine CXCL10 as a biomarker in kidney transplantation – Section: URINE CXCL10 IN REJECTION
A randomized trial has been conducted to evaluate whether routine monitoring of urine CXCL10 actually improves clinical outcomes for transplant recipients, not just whether the test can detect rejection.27PubMed Central. Randomized Trial to Assess the Clinical Utility of Renal Allograft Monitoring by Urine CXCL10 Chemokine The concept is appealing: if serial urine tests could flag rejection before kidney function visibly deteriorates, doctors could adjust anti-rejection drugs earlier and potentially prevent irreversible damage. Whether this strategy moves into standard practice will depend on ongoing trial results and validation across different transplant centers.
Cardiovascular Disease and Preeclampsia
CXCL10 also shows up in atherosclerosis, the buildup of fatty plaques in arteries. In a study of over 100 human carotid artery specimens removed surgically, increasing CXCL10 concentrations were strongly associated with a more unstable plaque type: high in inflammatory cells, low in the structural proteins and smooth muscle cells that keep plaques from rupturing.28PubMed Central. Atherosclerotic Plaque Stability Is Affected by the Chemokine CXCL10 in Both Mice and Humans – Section: Results In other words, CXCL10 marks the kind of plaque that is more likely to break open and cause a heart attack or stroke.
In pregnancy, CXCL10 has been linked to preeclampsia, a serious condition involving high blood pressure and organ damage. Women with preeclampsia had significantly higher blood levels of CXCL10 than women with normal pregnancies.29PubMed Central. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? – Section: RESULTS Because CXCL10 both promotes inflammation and inhibits new blood vessel growth, researchers have suggested it could be a molecular link between the two hallmarks of preeclampsia: an exaggerated inflammatory response and poor blood vessel development in the placenta. Confirmatory work has found elevated CXCL10 alongside other inflammatory markers like IL-6 and C-reactive protein in preeclamptic patients.30PubMed. Specific inflammatory profile in each pregnancy complication: A comparative study – Section: RESULTS
Interpreting a CXCL10 Test Result
If you have had a CXCL10 or IP-10 test, the first thing to understand is that it is not disease-specific. An elevated result tells you that something has activated the interferon pathway and triggered immune cell recruitment, but it does not point to a single diagnosis. The same high reading could reflect an active viral infection, an autoimmune flare, transplant rejection, or tumor immune activity. The value of the test comes from the clinical context: a transplant nephrologist tracking urine CXCL10 over time is asking a very different question than an infectious disease specialist using IP-10 as part of a tuberculosis workup.
Reference ranges vary by assay and specimen type, and there is no single universal cutoff. In the TB diagnostic setting, for example, IP-10 levels are interpreted after antigen stimulation of blood samples, not from a static blood draw. In transplant monitoring, the ratio of urine CXCL10 to urine creatinine (to account for how dilute or concentrated the sample is) is often the reported value. In research on COVID-19 severity, plasma levels are compared against healthy-control baselines established within each study.
One complication worth knowing about is that CXCL10 can exist in two forms. An enzyme called DPP4 (the same enzyme targeted by some diabetes drugs) clips a piece off the front of the CXCL10 molecule, creating a truncated version that actually blocks the receptor instead of activating it. The full-length form attracts immune cells; the clipped form can counteract that effect. Standard clinical assays usually measure total CXCL10 without distinguishing the two, though specialized research assays can tell them apart.31Oxford Academic (Clinical and Experimental Immunology). Discrimination of agonist and antagonist forms of CXCL10 in biological samples This means a high total CXCL10 level does not always mean high immune cell recruitment, because some fraction of that total may be the inactive, antagonist form.
Targeting CXCL10 as Therapy
Given how broadly CXCL10 participates in disease, it is a natural drug target. The most concrete clinical data come from rheumatoid arthritis. A fully human antibody called MDX-1100, designed to neutralize CXCL10 directly, was tested in a randomized, double-blind trial in RA patients who had not responded well to methotrexate alone. The treatment group had a significantly higher response rate than the placebo group: roughly 54% versus 17% achieved at least a 20% improvement in symptoms. The drug was well tolerated. This was described as the first demonstration of clinical efficacy for a chemokine-targeted therapy in rheumatoid arthritis.32PubMed. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis – Section: RESULTS
In cancer, the therapeutic logic flips depending on the context. Some researchers are trying to increase CXCL10 inside tumors to boost immune cell infiltration and make immunotherapy more effective, while others are exploring receptor blockade in cancers where the CXCL10-CXCR3 axis drives tumor cell migration. The CXCR3 inhibitor AMG487, for instance, has shown activity against pancreatic cancer cell growth in laboratory models.25PubMed. CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK/MAPK signaling The challenge for drug developers is specificity: blocking CXCL10 broadly could suppress needed anti-tumor immunity, while boosting it could fuel metastasis in the wrong tumor types. Any viable therapy will need to account for this double-edged biology.
Why One Chemokine Shows Up Everywhere
It might seem odd that a single molecule appears relevant to tuberculosis, COVID-19, lupus, rheumatoid arthritis, multiple sclerosis, diabetes, liver cancer, kidney transplant rejection, atherosclerosis, and preeclampsia. The explanation is that CXCL10 is not itself the cause of any of these diseases. It is a downstream output of interferon signaling and a universal recruiter of a particular type of immune cell response. Any condition that activates the interferon pathway strongly enough and long enough will produce elevated CXCL10. That universality is both its strength as a biomarker, since it lights up early and reliably across many inflammatory states, and its weakness, since it cannot tell you which inflammatory state you are looking at without additional clinical information.
The ongoing research direction is toward combining CXCL10 with other markers into multiparameter panels, rather than relying on it alone. In transplant medicine, combining urine CXCL10 with donor-derived cell-free DNA and clinical lab values improves diagnostic precision.33Transplant International. Diagnostic Potential of Urine CXCL10 and Donor-Derived cfDNA in Kidney Transplant Rejection – Section: Results In tuberculosis, pairing IP-10 with interferon-gamma measurements improves the ability to separate active disease from latent infection. In cancer immunotherapy, CXCL10 may eventually serve as one indicator among several for predicting whether a tumor will respond to checkpoint blockade. The future of CXCL10 testing is less likely to be a standalone diagnostic and more likely to be a component that sharpens the accuracy of broader clinical models.